Jim Simons’s Iterum Therapeutics ITRM Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2025
Q4
Sell
-81,694
Closed -$54.7K 3495
2025
Q3
$54.7K Sell
81,694
-390,206
-83% -$306K ﹤0.01% 3327
2025
Q2
$470K Buy
471,900
+231,000
+96% +$241K ﹤0.01% 2865
2025
Q1
$296K Sell
240,900
-197,916
-45% -$294K ﹤0.01% 2929
2024
Q4
$777K Buy
+438,816
New +$688K ﹤0.01% 2623
2024
Q3
Sell
-64,022
Closed -$73.3K 3705
2024
Q2
$73.3K Sell
64,022
-46,304
-42% -$67.1K ﹤0.01% 3237
2024
Q1
$170K Buy
110,326
+60,404
+121% +$98.2K ﹤0.01% 3267
2023
Q4
$98K Buy
49,922
+3,000
+6% +$3.72K ﹤0.01% 3305
2023
Q3
$38K Buy
46,922
+4,138
+10% +$3.93K ﹤0.01% 3440
2023
Q2
$46K Buy
42,784
+3,900
+10% +$4.32K ﹤0.01% 3632
2023
Q1
$39K Buy
38,884
+1,800
+5% +$2.08K ﹤0.01% 3710
2022
Q4
$31K Buy
37,084
+2,400
+7% +$3.41K ﹤0.01% 3883
2022
Q3
$56K Buy
34,684
+13,131
+61% +$39.8K ﹤0.01% 3724
2022
Q2
$65K Buy
21,553
+14,346
+199% +$53.7K ﹤0.01% 3949
2022
Q1
$38K Sell
7,207
-1,273
-15% -$7.36K ﹤0.01% 3943
2021
Q4
$50K Sell
8,480
-34,491
-80% -$266K ﹤0.01% 3783
2021
Q3
$360K Sell
42,971
-176,316
-80% -$2.17M ﹤0.01% 3017
2021
Q2
$7.6M Buy
+219,287
New +$4.75M 0.01% 1368
2021
Q1
Sell
-48,860
Closed -$725K 3504
2020
Q4
$725K Buy
+48,860
New +$572K ﹤0.01% 2658

Other funds holding ITRM

Jim Simons's ITRM Position: Q4 2025 in Review

Jim Simons sold out of Iterum Therapeutics (ITRM) in Q4 2025, closing a stake of 81,694 shares — an estimated $54.7K sold.

Jim Simons first reported a position in ITRM in Q4 2020 and held it in 18 quarters. The position peaked at $7.6M in Q2 2021. 20 funds tracked by Wall St. Rank hold ITRM as of Q4 2025.

  • Jim Simons reported no remaining Iterum Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Jim Simons sold 81,694 Iterum Therapeutics shares in Q4 2025, an estimated $54.7K.
  • Jim Simons first reported a position in Iterum Therapeutics in Q4 2020 and held it in 18 quarters.
  • Jim Simons's Iterum Therapeutics position peaked at $7.6M in Q2 2021.
  • 20 funds tracked by Wall St. Rank held Iterum Therapeutics as of Q4 2025.

Based on Renaissance Technologies's 13F filing for Q4 2025, filed 12 Feb 2026.